Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

BACKGROUNDS: Papillary thyroid cancer (PTC), which is often driven by acquired somatic mutations in BRAF genes, is the most common pathologic type of thyroid cancer. PTC has an excellent prognosis after treatment with conventional therapies such as surgical resection, thyroid hormone therapy and adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dong, Su, Xi, Zhu, Lizhang, Jia, Hao, Han, Bin, Chen, Haibo, Liang, Qingzhuang, Hu, Chenchen, Yang, Hao, Liu, Lisa, Li, Peng, Wei, Wei, Zhao, Yongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827684/
https://www.ncbi.nlm.nih.gov/pubmed/36624452
http://dx.doi.org/10.1186/s12967-022-03848-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827684/
https://www.ncbi.nlm.nih.gov/pubmed/36624452
http://dx.doi.org/10.1186/s12967-022-03848-z

Ejemplares similares